deepeye empowers the field of ophthalmology with AI-driven optimal therapy planning support, enabling additional insights into treatment data of patients suffering from retinal eye diseases. These conditions such as Age-related Macular Degeneration (AMD) are prevalent in over 12% of the European and US population, causing more than 66% of cases of blindness. Through our precision medicine platform, we aim to address the root causes of these vision impairments.

The Digital Therapy Assistant

At deepeye, we’re pioneering a shift in retinal therapy through our specialized AI tools for ophthalmology. Our innovation supports the therapy process, enabling doctors to make more informed decisions, thereby potentially improving patient outcomes.

Highlights of AI and 2nd opinion

• Based on proven clinical method using human expert 2nd opinion leading to 3x better outcomes and keeping almost 2x more patients in vision-preserving treatment compared to state-of-the-art.

• Focus on reducing therapy burden on clinicians and patients to improve treatment adherence.

• Aims at boosting therapy effectiveness and efficiency in response to the growing prevalence of retinal diseases worldwide.